Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA's expert groupsApellis anticipates a CHMP opinion no later than July 2024 ...
Apellis Pharma Gets Negative CHMP Opinion for Intravitreal Pegcetacoplan
Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal...
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension studyWell-demonstrated safety profile consistent with previously reported...
SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12 months for GA, a chronic disease and leading cause of...
Empaveli is the first treatment for PNH that binds to the complement protein C3.
In as early as 12 weeks: 80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline40% of patients showed zero staining...
WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a...
Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research...
Internal structural variations were identified in the 19-gauge filter needle included in certain injection kits; Apellis recommends use of kits with the 18-gauge filter needle, which are already in...